Novo Nordisk

News

Novo rapped by FDA for not reporting drug adverse effects

Novo Nordisk has been sent a warning letter from the FDA for violations of postmarketing adverse drug experience (PADE) regulations.

News

Novo partners with Hims & Hers again, ending GLP-1 spat

Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

News

Novo Nordisk plans €432m investment in Irish GLP-1 plant

Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Novo pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.

Novo rapped by FDA for not reporting drug adverse effects

Novo partners with Hims & Hers again, ending GLP-1 spat

FDA ramps up its pushback against compounded GLP-1s

Novo Nordisk plans €432m investment in Irish GLP-1 plant

Lilly says orforglipron tops Novo pill in diabetes trial

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Regenxbio, Solid report data with Duchenne gene therapies

Using AI-driven synthetic personas to take your insights fur...

Novo Nordisk

Editor's Picks